

press release

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

- *Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss intervention.¹*
- *When adhering to treatment, weight loss of $\geq 5\%$, $\geq 20\%$, $\geq 25\%$, and $\geq 30\%$ was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks.^{1*}*
- *The REDEFINE clinical program is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 11.²*

MISSISSAUGA, ON, June 24, 2025 – This week, *The New England Journal of Medicine (NEJM)* published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.¹ REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.¹ These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in *NEJM*.

Dr. Harpreet Bajaj, Medical Director of Endocrine and Metabolic Research at LMC Healthcare/Centricity Research in Canada and clinical investigator on REDEFINE 2, stated: "In the newly published primary results of REDEFINE 1 and 2 trials, CagriSema, a dual-agonist (incretin and amylin), led to incremental benefits on weight loss and glucose levels compared to semaglutide alone, representing a new era for the next generation of obesity medications. The average weight reduction of over 20% from baseline in REDEFINE 1 among participants with overweight or obesity is very promising. The weight loss in REDEFINE 2, along with over 80%* of the participants achieving HbA1C target of $\leq 6.5\%$ among participants with type 2 diabetes, marks a significant scientific advancement for Canadians living with obesity who require support beyond currently available GLP-1 RAs. These results are especially relevant to real-world practices, considering the flexibility in both the study protocols."

CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group if all patients adhered to treatment.^{1*} When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.^{1**} In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI < 30 kg/m²) at the end of treatment, from a mean BMI of 38 kg/m² at the start of treatment. In the placebo group, 10.2% reached that threshold at 68 weeks.¹

Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body weight reduction of ≥25%.^{*} Additionally, 23.1% lost ≥30% of their body weight.^{1*} When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction and 19.3% achieved ≥30% body-weight reduction.^{1**} In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus -5.7% and -4.3% for the placebo group, respectively.¹

Safety data generated in the REDEFINE 1 and 2 trials was comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 5.9% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.^{1,3} In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo) including nausea (55% vs. 12.6%), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and were mostly transient and mild-to-moderate in severity.¹

Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in *NEJM*.³ In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was -15.7% with CagriSema versus -3.1% with placebo.^{3*} When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was -13.7% with CagriSema versus -3.4% with placebo.^{3**} A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by ≥5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.8% vs. 2.4%), and ≥20% (22.9% vs. 0.5%).³ The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.³

The REDEFINE clinical program will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of

CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2.

* Based on the trial product estimand; this estimand estimates what the effect would be if all participants adhered to treatment

** Based on the treatment policy estimand: treatment effect regardless of treatment adherence

About CagriSema

CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg.

About the REDEFINE clinical trial program

REDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes.¹ REDEFINE 2 was a double-blind, randomized, placebo- and controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight.³

Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2.

About Obesity in Canada

Over 8 million Canadian adults are living with obesity, and many require support to effectively manage their condition.⁴ The prevalence of obesity, which increases the risk of serious chronic illness, has grown over the last two decades.^{4,5} Obesity is not a personal failure or a lack of willpower—obesity is a chronic disease.⁶ Despite its widespread impact, obesity often goes untreated, leading to significant personal, societal, and economic consequences.⁷ Just like other chronic diseases, obesity requires long-term management.⁸

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit [novonordisk.ca](https://www.novonordisk.ca), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Kate Hanna

905-301-7334

kxyh@novonordisk.com

Amy Snow

647-202-6367

easw@novonordisk.com

References:

¹ Garvey T, Blüher M, Contreras C, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2025;10.1056/NEJMoa2502081.

² ClinicalTrials.gov. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: <https://clinicaltrials.gov/study/NCT07011667>.

³ Davies M, Bajaj H, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. *N Engl J Med*. 2025;10.1056/NEJMoa2502082.

⁴ Statistics Canada. An overview of weight and height measurements on World Obesity Day. <https://www.statcan.gc.ca/o1/en/plus/5742-overview-weight-and-height-measurements-world-obesity-day>

⁵ Twells LK, Janssen I, Kuk JL. Canadian Adult Obesity Clinical Practice Guidelines: Epidemiology of Adult Obesity. <https://obesitycanada.ca/guidelines/epidemiology>

⁶ Obesity Canada. Five Facts about Obesity. <https://obesitycanada.ca/understanding-obesity/5-facts/>

⁷ Obesity Canada. Cost of Inaction on Obesity. <https://obesitycanada.ca/understanding-obesity/cost-of-inaction/>

⁸ Wharton et al. Obesity in adults: a clinical practice guideline. *CMAJ*. 2021 August 4; 192:E875-91. doi: 10.1503/cmaj.191707. Available at: <https://www.cmaj.ca/content/cmaj/192/31/E875.full.pdf>